CENTRE FOR DATA ENRICHED MEDICINE (TEAMPERMED)

Informazioni relative al progetto

TeamPerMed

ID dell’accordo di sovvenzione: 101060011

DOI

10.3030/101060011

Data della firma CE 28 Aprile 2023

Data di avvio 1 Settembre 2023

Data di completamento 31 Agosto 2029

Finanziato da

• Widening participation and spreading excellence

Costo totale

€ 15 000 000,00

Contributo UE

€ 15 000 000,00

Coordinato da

TARTU ULIKOOL
Estonia

Periodic Reporting for period 1 - TeamPerMed (CENTRE FOR DATA ENRICHED MEDICINE (TEAMPERMED))

Periodo di rendicontazione: 2023-09-01 al 2025-02-28

Sintesi del contesto e degli obiettivi generali del progetto

Through this project, the University of Tartu along with Tartu University Hospital will form the independent Centre for Personalised Medicine (TeamPerMed) which will be a multi-disciplinary centre that integrates expertise in Genomics, IT, Clinical Medicine and Socio-Economic Analysis to create a scalable framework for developing clinical guidelines and clinical decision support (CDS) tools that can be effectively integrated into healthcare systems.
With the guidance from our expert partners, Erasmus Medical Centre and the University of Helsinki, TeamPerMed will seek to become a recognized regional/European leader in using electronic health and genomics data to make discoveries regarding the causes and development of disease.
TeamPerMed will contribute to digital transformation in healthcare by developing tools and protocols that will allow to make better use of health care data in research and treatment. Indirectly, we will contribute to green transformation, as our research results will enable healthcare systems to operate more efficiently. The technology, tools and knowledge developed by TeamPerMed will contribute to Europe’s competitiveness in the emerging personalised medicine sector, improving the quality of healthcare and lives of European citizens and paving the way for the ‘next generation’ of medicine.
TeamPerMed’s achievements will make it a role model for institutional and systemic reforms in widening countries, contributing to the improved R&I culture and closure of gaps in R&I performance among EU member states.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Participant recruitment to the clinical study called "Pragmatic trial assessing polygenic risk driven statin therapy for cardiovascular disease prevention" began in March 2025. This research investigates the potential advantages of intensive preventive statin treatment for healthy men aged 45-80 and women aged 55-80 who possess a high genetic predisposition to coronary artery disease (CAD).

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

.